GlassScriptPhysician profile
David E Foster
NPI 1285695957
$7,990.17
in general payments reported to CMS, 2019-2025
23 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $1,717 · 2023: $1,793 · 2024: $2,032 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,058 · Education: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,057.83 |
| Education | $657.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,681.96 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,074.54 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,053.23 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $676.88 | 2021-2025 | Ilumya |
| Incyte Corporation | $426.88 | 2022-2024 | Opzelura |
| Genzyme Corporation | $375.10 | 2021-2025 | |
| Glaukos Corporation | $278.56 | 2024-2025 | Idosetr, Idose |
| E.R. Squibb & Sons, L.L.C. | $266.24 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $257.43 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $246.69 | 2022-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $220.10 | 2021-2025 | |
| Ucb, INC. | $201.51 | 2022-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $178.94 | 2024-2025 | |
| Amgen INC. | $166.03 | 2022-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157.57 | 2021-2025 | Cabtreo, Siliq, Jublia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $134.52 | 2025 | Rocklatan |
| Pfizer INC. | $120.14 | 2022-2023 | |
| Dermavant Sciences, INC. | $117.76 | 2024 | Vtama |
| Lilly USA, LLC | $115.83 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Scientific Affairs, LLC | $107.52 | 2022 | |
| Arcutis Biotherapeutics, INC. | $94.05 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.54 | 2025 | Spevigo |
| Organon LLC | $13.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.